(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 69.7% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.89%.
Agios Pharmaceuticals's revenue in 2024 is $31,306,000.On average, 5 Wall Street analysts forecast AGIO's revenue for 2024 to be $2,079,671,474, with the lowest AGIO revenue forecast at $1,987,277,031, and the highest AGIO revenue forecast at $2,138,612,757. On average, 5 Wall Street analysts forecast AGIO's revenue for 2025 to be $3,627,164,610, with the lowest AGIO revenue forecast at $3,323,127,723, and the highest AGIO revenue forecast at $4,095,167,497.
In 2026, AGIO is forecast to generate $9,025,412,357 in revenue, with the lowest revenue forecast at $5,859,992,390 and the highest revenue forecast at $12,360,032,493.